- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Oncology Care Model: Additional Concerns
Bruce Feinberg, DO; Scott Gottlieb, MD; Brian Kiss, MD; and Ted Okon, MBA, continue to discuss the Oncology Care Model established by the CMS and how it is likely to affect physicians and their practices.
Dr Kiss explains why his organization opted not to participate in the Oncology Care Model, but rather to collaborate with healthcare systems independently.
The Oncology Care Model will impact the physician’s choice to see and care for Medicare patients, projects Dr Gottlieb. Additionally, he remarks, the new model is likely to further affect community practices and result in consolidation because of its complex structure and burden on physicians.
Because the model includes a vast number of performance-based measures, and because these measures are constantly changing, physicians don’t understand how they are being measured, explains Mr Okon. To describe the effect of this issue, he compares a physician who attempts to work under the new model with an athlete who tries to play golf blindfolded.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
